

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

This checklist is intended as an aid to support clinical decision making for prescribers. However, use of this checklist is not required to prescribe PAXLOVID under the EUA.

Medical History

- Positive SARS-CoV-2 test (Confirmation of a positive home rapid SARS-CoV-2 test result with additional direct SARS-CoV-2 viral testing is not required.)
- Age \geq 18 years OR \geq 12 years of age and weighing at least 40 kg
- Has one or more risk factors for progression to severe COVID-19¹ (Healthcare providers should consider the benefit-risk for an individual patient.)
- Symptoms consistent with mild to moderate COVID-19²
- Symptom onset within 5 days (Prescriber is encouraged to include a note to the pharmacist in the prescription stating: Please fill prescription by [insert date]. This prescription fill by date is within 5 days from symptom onset and complies with the patient eligibility criteria under the EUA.)
- Not requiring hospitalization due to severe or critical COVID-19 at treatment initiation
- No known or suspected severe renal impairment (eGFR \leq 30 mL/min)
 - Note that a dose reduction is required for patients with moderate renal impairment (eGFR \geq 30- $<$ 60 mL/min); see the Fact Sheet for Healthcare Providers.
 - Prescriber may rely on patient history and access to the patient's health records to make an assessment regarding the likelihood of renal impairment. Providers may consider ordering a serum creatinine or calculating the estimated glomerular filtration rate (eGFR) for certain patients after assessment on a case-by-case basis based on history or exam.
- No known or suspected severe hepatic impairment (Child-Pugh Class C)
- No history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product

NOTES: _____

Concomitant Medications

- HMG-CoA reductase inhibitors (statins)
 - *If the patient is taking lovastatin or simvastatin*, which are contraindicated with PAXLOVID coadministration, PAXLOVID can be given if the statin can be held 12 hours prior to the first dose of PAXLOVID treatment, held during the 5 days of treatment, and restarted 5 days after completing PAXLOVID.
 - *If the patient is taking atorvastatin or rosuvastatin*, consider temporary discontinuation of atorvastatin and rosuvastatin during treatment with

¹ <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>.

² <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/#:~:text=Patients%20with%20mild%20illness%20may,on%20exertion%2C%20or%20abnormal%20imaging>

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

PAXLOVID . Atorvastatin and rosuvastatin do not need to be held prior to or after completing PAXLOVID.

- Hormonal contraceptives containing ethinyl estradiol: *If the patient is taking a hormonal contraceptive containing ethinyl estradiol, consider an additional non-hormonal method of contraception during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID.*

- Medications for HIV-1 Treatment: *If the patient is taking medications for the treatment of HIV-1 infection, with the exception of maraviroc³, HIV antiretroviral medications can be co-administered with PAXLOVID without dose adjustment, but arranging follow-up by the HIV care provider to monitor for side effects is recommended^{4,5,6}.*

- Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID
 - Patient is not taking any other medications
 - Patient is not taking any of the medications listed below.
 - In addition, the patient’s other medications have been checked for contraindications, the need for dose adjustment, or increased monitoring due to drug interactions with a strong CYP3A inhibitor such as ritonavir based on appropriate resources such as the prescribing information of these medications.
 - Patient is NOT taking any of the medications listed in RED but is taking one or more of the medications listed below in YELLOW, and dose adjustment, holding of medication, or increased monitoring is planned (additional resources which include instructions for managing specific drug interactions are included at the end of this document).
 - In addition, the patient’s other medications not listed below have been checked for contraindications, the need for dose adjustment, or increased monitoring due to drug interactions with a strong CYP3A inhibitor such as ritonavir based on appropriate resources such as the prescribing information of these medications.

NOTES: _____

³ Please see the maraviroc prescribing information here:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022128Orig1s019,208984Orig1s002lbl.pdf

⁴ Exposure of certain HIV medications may be altered with PAXLOVID co-administration.

⁵ Patients on ritonavir- or cobicistat-containing HIV or HCV regimens should continue their treatment as indicated.

⁶ PAXLOVID use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID (listed alphabetically by generic name)

Interaction Codes:



Coadministration of this drug with PAXLOVID is CONTRAINDICATED. For further information, refer to the Fact Sheet for Healthcare Providers and the individual Prescribing Information for the drug.



Coadministration of this drug with PAXLOVID should be avoided and/or holding of this drug, dose adjustment of this drug, or special monitoring is necessary. Consultation with the prescriber of the potentially interacting drug is recommended. For further information, refer to the Health Care Provider Fact Sheet and the individual Prescribing Information for the drug.

*The table below provides a listing of clinically significant drug interactions, including contraindicated drugs, in addition to those listed under Concomitant Medications above (HMG-CoA reductase inhibitors [statins], hormonal contraceptives containing ethinyl estradiol, and medications for HIV-1 treatment). **Drugs listed in this table are a guide and are not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.***

Drug	Drug Class	Interaction Code
abemaciclib	Anticancer drug	***
alfuzosin	Alpha 1-adrenoreceptor antagonist	XXX
amiodarone	Antiarrhythmic	XXX
amlodipine	Calcium channel blocker	***
apalutamide	Anticancer drug	XXX
bedaquiline	Antimycobacterial	***
bepidil	Antiarrhythmic	***
betamethasone	Systemic corticosteroid	***
bosentan	Endothelin receptor antagonist	***
budesonide	Systemic corticosteroid	***
bupropion	Antidepressant	***
carbamazepine	Anticonvulsant	XXX
ceritinib	Anticancer drug	***
ciclesonide	Systemic corticosteroid	***

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Drug	Drug Class	Interaction Code
clarithromycin	Anti-infective	***
clozapine	Antipsychotic	XXX
colchicine	Anti-gout	XXX
cyclosporine	Immunosuppressant	***
dabigatran	Anticoagulants	***
dasabuvir	Hepatitis C direct acting antiviral	***
dasatinib	Anticancer drug	***
dexamethasone	Systemic corticosteroid	***
digoxin	Cardiac glycoside	***
dihydroergotamine	Ergot derivative	XXX
diltiazem	Calcium channel blocker	***
dronedarone	Antiarrhythmic	XXX
elbasvir/grazoprevir	Hepatitis C direct acting antiviral	***
encorafenib	Anticancer drug	***
ergotamine	Ergot derivative	XXX
erythromycin	Anti-infective	***
felodipine	Calcium channel blocker	***
fentanyl	Narcotic analgesic	***
flecainide	Antiarrhythmic	XXX
fluticasone	Systemic corticosteroid	***
glecaprevir/pibrentasvir	Hepatitis C direct acting antiviral	***
ibrutinib	Anticancer drug	***
isavuconazonium sulfate	Antifungal	***
itraconazole	Antifungal	***
ivosidenib	Anticancer drug	***
ketoconazole	Antifungal	***
lidocaine (systemic)	Antiarrhythmic	***
lurasidone	Antipsychotic	XXX
methadone	Narcotic analgesic	***
methylergonovine	Ergot derivative	XXX
methylprednisolone	Systemic corticosteroid	***
midazolam (administered parentally)	Sedative/hypnotic	***
midazolam (oral)	Sedative/hypnotic	XXX
mometasone	Systemic corticosteroid	***
neratinib	Anticancer drug	***
nicardipine	Calcium channel blocker	***
nifedipine	Calcium channel blocker	***
nilotinib	Anticancer drug	***
ombitasvir/paritaprevir /ritonavir	Hepatitis C direct acting antiviral	***
pethidine	Analgesic	XXX
phenobarbital	Anticonvulsant	XXX

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Drug	Drug Class	Interaction Code
phenytoin	Anticonvulsant	XXX
pimozide	Antipsychotic	XXX
prednisone	Systemic corticosteroid	***
propafenone	Antiarrhythmic	XXX
propoxyphene	Analgesic	XXX
quetiapine	Antipsychotic	***
quinidine	Antiarrhythmic	XXX
ranolazine	Antianginal	XXX
rifabutin	Antimycobacterial	***
rifampin	Antimycobacterial	XXX
rivaroxaban	Anticoagulant	***
salmeterol	Long-acting beta-adrenoceptor agonist	***
sildenafil (Revatio®) when used for pulmonary arterial hypertension	PDE5 inhibitor	XXX
sirolimus	Immunosuppressant	***
sofosbuvir/velpatasvir/ voxilaprevir	Hepatitis C direct acting antiviral	***
St. John's Wort (hypericum perforatum)	Herbal product	XXX
tacrolimus	Immunosuppressant	***
trazodone	Antidepressant	***
triamcinolone	Systemic corticosteroid	***
triazolam	Sedative/hypnotic	XXX
venetoclax	Anticancer drug	***
vinblastine	Anticancer drug	***
vincristine	Anticancer drug	***
voriconazole	Antifungal	***
warfarin	Anticoagulant	***

ADDITIONAL RESOURCES:

PAXLOVID - Fact Sheet for Healthcare Providers: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs>

Prescribing Information (Label/Package Insert) for Individual Drugs (Drugs@FDA): <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>

University of Liverpool COVID-19 Drug Interactions: <https://www.covid19-druginteractions.org/checker>

NIH COVID-19 Treatment Guidelines: <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/>